About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium

By: via GlobeNewswire

NEWPORT BEACH, Calif., Jan. 24, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB), today announced that Northstrive Biosciences Inc. (“Northstrive Biosciences”) has been invited to present at the upcoming symposium called Anti-Obesity Treatments: Challenges and Emerging Solutions organized by UCLA Metabolism Theme. UCLA Metabolism Theme is an initiative at UCLA David Geffen School of Medicine aiming to facilitate campus wide interdisciplinary research in the field of metabolism involving basic, clinical, and industry collaborations

This timely symposium brings together industry leading, obesity focused clinicians, researchers, drug developers and investors to address the challenges brought up by weight loss treatments. Northstrive Biosciences has been invited to present lead asset EL-22, which leverages a first-in-class engineered probiotic approach for preserving muscle while on weight loss treatments.

“The rise of anti-obesity medications has put the spotlight on the challenges being faced, particularly the management of muscle and bone loss associated with GLP-1 receptor agonists,” stated Orian Shirihai, MD, PhD, the Director of UCLA’s Metabolism Theme. “We organized this event to gather obesity’s leading opinion leaders to review the gaps and highlight the emerging solutions. I am pleased that Northstrive Biosciences has accepted our invitation to give a talk at the event.”

Northstrive Biosciences will showcase EL-22, a first-in-class engineered probiotic designed to preserve muscle mass in patients undergoing weight-loss treatments, including GLP-1 receptor agonists. This groundbreaking therapeutic addresses a critical gap in current obesity treatments, where up to 50% of body weight lost is lean muscle mass—a side effect that has yet to be adequately addressed by approved therapies.

[1][2] Studies show that approximately 30-50% of body weight lost with GLP-1 based therapy is lean muscle mass, a common side effect that has no currently approved treatment. Northstrive’s lead asset EL-22 is being developed as a potential combination therapy with GLP-1 receptor agonists for preserving muscle while on weight loss treatments.

“We are looking forward to presenting EL-22 as a next-generation solution to the common muscle wasting side effect,” said Deniel Mero, Co-founder of Northstrive Biosciences. “We’re honored to contribute a lecture and are looking to connect with key opinion leaders, investors and established pharma companies in the obesity space.”

Northstrive Biosciences’ management is scheduled to present on Friday, February 7th at 11:30 am PT.

About Northstrive Biosciences

Northstrive Biosciences Inc., a PMGC Holdings company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Its lead asset, EL-22, is leveraging an engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com

About PMGC Holdings Inc.

PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. Currently, our portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC Holdings’ filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

IR Contact:
IR@pmgcholdings.com

1 Reference: Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. Endocrinol Metab (Seoul). 2019 Sep;34(3):247-262. doi: 10.3803/EnM.2019.34.3.247

2 Reference: Beavers KM, Cortes TM, Foy CM, et al. GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials. Obesity (Silver Spring). 2024; 1-13. https://doi.org/10.1002/oby.24172


Primary Logo

More News

View More
This AI Chip Giant Could Be the Market’s Next Big Winner
Via MarketBeat
Topics Artificial Intelligence
Tickers AMD TSM
Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock
Via MarketBeat
Topics Artificial Intelligence
Tickers AMD AVGO NVDA
Institutions Are Fueling CrowdStrike’s Next Leg Higher
Via MarketBeat
Topics Artificial Intelligence
Tickers CRWD DDOG ZS
Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up
Via MarketBeat
Topics Artificial Intelligence
Tickers AMZN MSFT NVDA
This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave
Via MarketBeat
Topics Artificial Intelligence
Tickers AMD ASML NVDA

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.16
+1.35 (0.74%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.